# Rakovina gains exclusivity and additional AI drug optimization under amended deal

_Published Wednesday, October 14, 2026 at 10:20 AM EDT · AI · Latest · Tier 2 — Notable_

![Rakovina gains exclusivity and additional AI drug optimization under amended deal — Primary](https://cdn.rttnews.com/images/v4/RTTNews-logo-512x512.png)

Rakovina Therapeutics amended and extended its research agreement with Variational AI, gaining exclusivity over the target product profile for its kt-5000 cancer drug program, RTTNews reported. During the agreed term, Variational AI cannot supply other parties with compounds intended to meet Rakovina's defined combination of potency, selectivity, drug-like properties and brain penetration.

Variational AI will provide additional AI lead optimization cycles beyond the five completed, at no additional cost through year-end. In exchange, it will receive increased milestone payments when a drug candidate is nominated and an out-licensing transaction is completed.

Rakovina retains control over candidates advancing to laboratory testing. The program remains preclinical and targets ATR, a regulator of the cellular response to DNA damage.

## Sources

- [RTTNews](https://www.rttnews.com/3698958/rakovina-variational-ai-extend-partnership-to-optimize-atr-inhibitor-candidates.aspx)

---
Canonical: https://techandbusiness.org/newswire/yon3lYFyxfCcnKTWU7E3Nq
Published: 2026-10-14T14:20:11.263Z
Story chronology: 2026-10-14T13:05:23.000Z
Retrieved: 2026-10-14T17:03:31.068Z
Publisher: Tech & Business (techandbusiness.org)